Our Q&As are emailed in our Saturday Morning Report, find the answer to this question below.
Hi James Quite a while since you reviewed Clinuval Pharma. The Share Price has fallen against a reasonable Report for FY 24 and quickly rebounded today up ~5.0% (Wednesday). I would appreciate your thoughts and as always clarity
Hi Richard,
This high Beta biotech stock has been under pressure for a few years having tumbled ~75% from its 2022 high, albeit with a few bounces along the way. At the end of February, CUV posted revenue of $35.6mn, up from $32.3mn YoY, and earnings per diluted share of 28c, up from 21.2c YoY – a decent beat to expectations. .
As you mentioned, the stock rallied sharply on Wednesday after introducing its “Groundbreaking” Vitiligo Program at the world’s largest Dermatology meeting in the US, although its Phase 3 Trial for SCENSSE and NB-UVB Light have been delayed by ~ 12 months. Importantly, this stock has experienced similar gains 5 times in recent years before falling away, i.e. its not for the fainthearted.
Take a free trial.
No payment details required.
Forgot password? Request a One Time Password or reset your password
One Time Password
Check your email for an email from [email protected]
Subject: Your OTP for Account Access
This email will have a code you can use as your One Time Password for instant access
A link to create a new password will be sent to the email address you have registered to your account.
Hi, this is only available to members. Join today and access the latest views on the latest developments from a professional money manager.
Our Smart Phone App will give you access to much of our content and notifications. Download for free today.
